- $1.51bn
- $1.37bn
- $124.46m
- 39
- 12
- 96
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.04 | ||
| Price to Tang. Book | 9.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.12 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.6% | ||
| Return on Equity | -49.83% | ||
| Operating Margin | -50.84% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.28 | 7.57 | 10.1 | 52.16 | 124.46 | 207.25 | 362.41 | 116.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Directors
- David Mott NEC (55)
- Michael Raab PRE (56)
- Justin Renz CFO (49)
- Elizabeth Grammer CAD (57)
- Jeffrey Jacobs CSO (57)
- Robert Blanks OTH (61)
- Susan Rodriguez OTH (57)
- David Rosenbaum OTH (60)
- Robert Bazemore IND (53)
- William Bertrand IND (56)
- Muna Bhanji IND (58)
- Geoffrey Block IND (55)
- Onaiza Cadoret-Manier IND (57)
- Jan Lundberg IND (66)
- Richard Rodgers IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 18th, 2007
- Public Since
- June 19th, 2014
- No. of Shareholders
- 25
- No. of Employees
- 267
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 232,686,008
- Address
- 34175 Ardenwood Blvd, FREMONT, 94555-3653
- Web
- https://www.ardelyx.com/
- Phone
- +1 5107457047
- Auditors
- Ernst & Young LLP
Upcoming Events for ARDX
Q1 2024 Ardelyx Inc Earnings Call
Ardelyx Inc Annual Shareholders Meeting
Q2 2024 Ardelyx Inc Earnings Release
Similar to ARDX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Ardelyx share price?
As of Today at 19:02 UTC, shares in Ardelyx are trading at $6.48. This share price information is delayed by 15 minutes.
How has the Ardelyx share price performed this year?
Shares in Ardelyx last closed at $6.48 and the price had moved by +35.56% over the past 365 days. In terms of relative price strength the Ardelyx share price has outperformed the S&P500 Index by +12.81% over the past year.
What are the analyst and broker recommendations for Ardelyx?
The overall consensus recommendation for Ardelyx is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ardelyx dividend yield?
Ardelyx does not currently pay a dividend.
Does Ardelyx pay a dividend?
Ardelyx does not currently pay a dividend.
When does Ardelyx next pay dividends?
Ardelyx does not currently pay a dividend.
How do I buy Ardelyx shares?
To buy shares in Ardelyx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ardelyx?
As of the previous close price of $6.48, shares in Ardelyx had a market capitalisation of $1.51bn.
Where are Ardelyx shares listed?
Here are the trading details for Ardelyx:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ARDX
What kind of share is Ardelyx?
Based on an overall assessment of its quality, value and momentum Ardelyx is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ardelyx share price forecast for 2024?
The analyst consensus target price for shares in Ardelyx is $13.65. That is 110.65% above the last closing price of $6.48.
Analysts covering Ardelyx currently have a consensus Earnings Per Share (EPS) forecast of -$0.45 for the next financial year.
What is the trend in the Ardelyx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ardelyx. Over the past six months, its share price has outperformed the S&P500 Index by +54.53%.
As of the last closing price of $6.48, shares in Ardelyx were trading +12.77% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ardelyx PE Ratio?
The Ardelyx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ardelyx?
Ardelyx's management team is headed by:
- David Mott - NEC
- Michael Raab - PRE
- Justin Renz - CFO
- Elizabeth Grammer - CAD
- Jeffrey Jacobs - CSO
- Robert Blanks - OTH
- Susan Rodriguez - OTH
- David Rosenbaum - OTH
- Robert Bazemore - IND
- William Bertrand - IND
- Muna Bhanji - IND
- Geoffrey Block - IND
- Onaiza Cadoret-Manier - IND
- Jan Lundberg - IND
- Richard Rodgers - IND